You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that the European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) without ...
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that Japan's Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorisation for Wayrilz (rilzabrutinib), an...
23 June 2026 - Clinical-stage oncology company Oxford BioTherapeutics (OBT) on Monday announced two new clinical milestones with Boehringer Ingelheim-partnered programmes, BI 3820768 (OB33) and obrixtamig (OBT620).BI 3820768 is the third programme fr...
23 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday the appointment of Paulo Fontoura, MD, PhD, FAAN, as executive vice president, global head of Research & Development Pharma, effective 1 Se...
22 June 2026 - Biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ: LABT) announced on Monday that it has secured a new composition of matter patent from IP Australia covering its Bisphosphocin compounds, strengthening its global intell...
22 June 2026 - Gene therapy company Genprex Inc (NASDAQ: GNPX) disclosed on Monday that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the use of its Reqorsa gene therapy (quaratusugene ozep...
22 June 2026 - French biotech company Transgene (Euronext Paris:TNG) announced on Monday that it has initiated a randomised Phase 1 trial of TG4070, an individualised neoantigen therapeutic vaccine, in combination with nivolumab for the adjuvant trea...